Characteristics of progression to tyrosine kinase inhibitors predict overall survival in patients with advanced non-small cell lung cancer harboring an EGFR mutation

• Published in: Journal of thoracic disease Vol. 10; no. 4; pp. 2166 - 2178
• Main Authors: Barrón, Feliciano, Cardona, Andrés F, Corrales, Luis, Ramirez-Tirado, Laura-Alejandra, Caballe-Perez, Enrique, Sanchez, Gisela, Flores-Estrada, Diana, Zatarain-Barrón, Zyanya Lucia, Arrieta, Oscar
• Format: Journal Article
• Language: English
• Published: China AME Publishing Company 01.04.2018
• Subjects: Original; afatinib; gefitinib; Lung adenocarcinoma; epidermal growth factor receptor (EGFR); patterns of progression; exon 19
• DOI: 10.21037/jtd.2018.03.106
• ISSN: 2072-1439

Non-small cell lung cancer (NSCLC) harboring EGFR-sensitizing mutations has a distinct biology and heterogeneous clinical behavior. We evaluated the characteristics to progression such as clinical patterns of progression (dramatic, gradual, and local) with the prognosis of NSCLC patients treated with tyrosine kinase inhibitors (TKIs). We reviewed 123 advanced-NSCLC patients with an EGFR-sensitizing mutation treated with TKIs (gefitinib, erlotinib and afatinib). We assessed patients according to clinical factors and progression pattern to TKIs at three centers. For all patients, 58.5%, 31.7% and 9.8% harbored exon19 deletion, exon21 L858R mutation and other-sensitivity mutations, respectively. Median progression-free survival (PFS) was 8.8 months (95% CI: 7.9-9.7). Sixty percent of patients were asymptomatic. Dramatic-progression was the most frequent pattern (50.4%), followed by gradual-progression (32.5%), and local-progression (17.1%). Median overall survival (OS) was 23.1 months (95% CI: 17.4-28.9). In the univariate analysis, factors associated to a longer OS included pattern [gradual-progression (32.1), dramatic (19.5) and local (18.8 months), P=0.008], and the time to progression to TKI [>12 months (38.5), 6-12 months (19.1), <6 months (9.6), P<0.001]. Multivariate analysis showed that only time to progression to TKI was independently associated to OS and PFS. Factors at TKI progression associated to a longer OS can define a subset of patients who may benefit from continued TKI therapy, as well as from local-ablative therapy in progression sites, especially in patients without T790M or who lack access to third-generation TKI.